Drug Library | Check Interactions | Compare Drugs | Conditions & Treatments | Interactive Tools


	• Drugs & Vitamins • Herbs & Supplements • Pill Images • Using Medicine


	• Drug Comparisons • Side Effect Comparisons


	• Health Conditions • Treatment Options


	• Care Paths • Check for Savings • Health Risk Assessments • Medication Card • Medication Checklist

Herbs & Supplements

Lesser Periwinkle
Scientific Name: Vinca Minor
Other Names: Common Periwinkle, Creeping Myrtle, Myrtle, Periwinkle

References

Beck WT, Cass CE, Houghton PJ. Microtubule-targeting anticancer drugs derived from plants and microbes: Vinca alkaloids, taxanes and epothilones. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer Medicine, 5th Edition. Atlanta: American Cancer Society; 2000:680-698.

Bennouna J, Delord JP, Campone M, Nguyen L. Vinflunine: a new microtubule inhibitor agent. Clinical Cancer Research. 2008;14(6):1625-1632.

Bernhardt P, McCoy E, O'Connor SE. Rapid identification of enzyme variants for reengineered alkaloid biosynthesis in periwinkle. Chemistry and Biology. 2007;14(8):888-897.

Blumenthal M, Gruenwald J, Hall T, Rister RS, eds.The Complete German Commission E Monographs. Austin, Texas: American Botanical Council; 1998.

Brinker F. Herb Contraindications and Drug Interactions. Sandy, Oregon: Eclectic Institute, 1997.

Dekoninck WJ, Jocquet P, Jacquy J, Henriet M. Comparative study of the clinical effects of vincamine + glycerol versus glycerol + placebo in the acute phase of stroke. Arzneimittelforschung. 1978;28(9):1654-1657.

Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. Journal of Clinical Oncology. 1986;4(9):1405-1417.

Dorr RT, Alberts DS. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. Journal of the National Cancer Institute. 1985;74(1):113-120.

Efferth T, Konkimalla VB, Wang YF, et al. Prediction of broad spectrum resistance of tumors towards anticancer drugs. Clinical Cancer Research. 2008;14(8):2405-2412.

Gruenwald J, Brendler T, Jaenicke C, eds. PDR for Herbal Medicines, 2nd edition. Montvale, NJ: Medical Economics Company, Inc; 2000.

Hoelzer KL, Harrison BR, Luedke SW, Luedke DW. Vinblastine-associated pulmonary toxicity in patients receiving combination therapy with mitomycin and cisplatin. Drug Intelligence in Clinical Pharmacology. 1986;20(4):287-289.

Jellin JM, Gregory P, Batz F, Hitchens K, et al, eds. Pharmacist's Letter/Prescriber's Letter. Natural Medicines Comprehensive Database, 3rd Edition. Stockton CA: Therapeutic Research Facility, 2000.

Kidd PM. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. Alternative Medicine Review. 1999;4(3):144-161.

Kris MG, Pablo D, Gralla RJ, Burke MT, Prestifilippo J, Lewin D. Dyspnea following vinblastine or vindesine administration in patients receiving mitomycin plus vinca alkaloid combination therapy. Cancer Treatment Reports. 1984;68(7-8):1029-1031.

Lee K, Tanaka M, Kanamaru H, et al. In vitro antagonism between cisplatin and vinca alkaloids. British Journal of Cancer. 1989;59(1):36-41.

Leveque D, Jehl F. Molecular pharmacokinetics of catharanthus (vinca) alkaloids. Journal of Clinical Pharmacology. 2007;47(5):579-588.

Linette DC, McGee KH, McFarland JA. Mitomycin-induced pulmonary toxicity: case report and review of the literature. Annals of Pharmacotherapy. 1992;26(4):481-484.

Luedke D, McLaughlin TT, Daughaday C, Luedke S, Harrison B, Reed G, Martello O. Mitomycin C and vindesine associated pulmonary toxicity with variable clinical expression. Cancer. 1985;55(3):542-545.

Martinez-Campa C, Casado P, Rodriguez R, et al. Effect of Vinca alkaloids on ERalpha levels and Estradiol-induced responses in MCF-7 cells. Breast Cancer Research and Treatment. Epublished ahead of print. March 23, 2006.

McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Product Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press; 1997.

Natural Medicines Comprehensive Database, Online Edition. Pharmacist's Letter/Prescriber's Letter. Stockton CA: Therapeutic Research Facility, 2006. Available at: http://www.pharmacistsletter.com/(S(ulqz3s45omt3ag5 5um4kj345))/home.aspx?li=1&st=1&cs=&s=ND.

Nicholson CD. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology (Berlin). 1990;101(2):147-159.

Noble RL. The discovery of the vinca alkaloids--chemotherapeutic agents against cancer. Biochemistry and Cellular Biology. 1990;68(12):1344-1351.

Ohio State University. Vinca minor. No Date Given. Available at: http://www.hcs.ohio-state.edu/hcs/TMI/Plantlist/vi_ minor.html Accessed February 21, 2003.

Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Safety. 2000;22(4):263-302.

Pasquier E, Kavallaris M. Microtubules: a dynamic target in cancer therapy. IUBMB Life. 2008 Mar;60(3):165-170.

Peirce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: Stonesong Press; 1999.

Rivera MP, Kris MG, Gralla RJ, White DA. Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy. American Journal of Clinical Oncology. 1995;18(3):245-250.

Rouzaud P, Estivals M, Pujazon MC, Carles P, Lauque D. Respiratory complications of the vinorelbine-mitomycin combination. [article in French] Revue Maladies Respiratorie. 1999;16(1):81-84.

Simoens C, Lardon F, Pauwels B, et al. Comparative study of the radiosensitizing and cell cycle effects of vinflunine and vinorelbine, in vitro. BMC Cancer. 2008;8:65.

Simoens C, Vermorken JB, Korst AE, et al. Cell cycle effects of vinflunine, the most recent promising Vinca alkaloid, and its interaction with radiation, in vitro. Cancer Chemotherapy and Pharmacology. 2006;58(2):210-218.

Slade JH. Neurological toxicities associated with cancer chemotherapeutic agents. US Pharmacist.2005;4(Oncology suppl):3-18.

Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia (Cochrane Review). Cochrane Database System Review. 2003;(1):CD003119.

Teicher BA. Newer cytotoxic agents: attacking cancer broadly. Clinical Cancer Research. 2008;14(6):1610-1617.

Thal LJ, Salmon DP, Lasker B, Bower D, Klauber MR. The safety and lack of efficacy of vinpocetine in Alzheimer's disease. Journal of the American Geriatric Society. 1989;37(6):515-520.

Thomas P, Pradal M, Le Caer H, Montcharmont D, Vervloet D, Kleisbauer JP. Acute bronchospasm due to periwinkle alkaloid and mitomycin association. [article in French] Revue Maladies Respiratorie. 1993;10(3):268-270.

Twohig KJ, Matthay RA. Pulmonary effects of cytotoxic agents other than bleomycin. Clinics in Chest Medicine. 1990;11(1):31-54.

Xiao WH, Bennett GJ. Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine. Pain. 2008;135(3):262-270.

Yun-San Yip A, Yuen-Yuen Ong E, Chow LW. Vinflunine: clinical perspectives of an emerging anticancer agent. Expert Opinion on Investigational Drugs. 2008;17(4):583-591.

Last Revised April 18, 2008

<< Back

Note: The above information is not intended to replace the advice of your physician, pharmacist, or other healthcare professional. It is not meant to indicate that the use of the product is safe, appropriate, or effective for you.

In general, herbal products are not subject to review or approval by the U.S. Food and Drug Administration (FDA). They are not required to be standardized, meaning that the amounts of active ingredients or contaminants they contain may vary between brands or between different batches of the same brand. Not all of the risks, side effects, or interactions associated with the use of herbal products are known because few reliable studies of their use in humans have been done.

This information is provided for your education only. Please share this information with your healthcare provider and be sure that you talk to your doctor and pharmacist about all the prescription and non-prescription medicines you take before you begin to use any herbal product.

Learn About

Who is this for?

When should I be careful taking it?

What side effects should I watch for?

What interactions should I watch for?

Should I take it?

References